SGLT2 inhibitor drugs.

(Photo by reporter Yan Hongjun)

[Reporter Yan Hongjun/Changhua Report] The "Slender Pen (GLP-1)" originally intended for diabetic patients to lower blood sugar has been snapped up by many obese people, causing a severe shortage in the market. Few people find ways to buy another hypoglycemic drug. Doctors remind the public that the main indication of SGLT2 inhibitors is diabetes. They are used to lose weight, which may cause risks such as urinary tract infection and ketoacidosis. If people without diabetes want to lose weight , it is better to follow diet control and exercise to lose weight is safer.

Both "SGLT2 inhibitor" and "GLP-1" are recent diabetes drugs, but their side effects can lead to weight loss and weight loss. The mechanism is to help the body secrete insulin, reduce glucagon, and stabilize blood sugar. It increases the brain's suppression of appetite and produces a sense of satiety, thereby reducing calorie intake and achieving weight loss. The main ingredient of the commonly known "Slim Pen" is GLP-1.

Please read on...

In China, the "slim pen" drugs with GLP-1 as the main ingredient include Saxenda, Victoza, Ozempic, and Trulicity, and the indications for Saxenda For obesity, it has been approved by the Ministry of Health and Welfare as a legal weight loss injection drug. The indications of the other three types are the control of type 2 diabetes, but they also wander in the gray area and are generally used for weight loss.

Taking hypoglycemic drugs to lose weight, the owner of a pharmacy in Changhua, surnamed Zhang, said that after many people could not buy the thin pen, they asked to buy drugs with SGLT2 inhibitors as the main component. Although they are prescription drugs, some people still sell them. A 60 to 100 yuan.

Chen Yinzheng, vice president of Changhua Hospital and a nephrologist at the hospital, said that the mechanism of SGLT2 inhibitors is different from that of GLP-1. It acts on the renal tubules, inhibiting the kidney’s ability to reabsorb urine sugar, allowing excess sugar to pass through the urine. Exhaust, achieve the effect of lowering blood sugar, effectively stabilize blood sugar, and also achieve weight loss because the heat is discharged.

Chen Yinzheng said that studies have shown that the use of SGLT2 inhibitors in diabetic patients can reduce proteinuria, slow down the deterioration of kidney disease, and even the occurrence of kidney dialysis.

It was further used in non-diabetic kidney patients and found to have similar effects.

In addition to the protective effect on the kidneys, SGLT2 inhibitors also have a protective effect on the heart, not only improving heart function, but also reducing hospitalization for heart failure and even death.

Chen Yinzheng pointed out that SGLT2 inhibitors are beneficial to blood sugar, kidneys, and heart. Diabetes and heart failure are currently covered by health insurance. Although health insurance has not yet paid for kidney disease, it should be just around the corner.

Chen Yinzheng emphasized that SGLT2 inhibitors are prescription drugs, and the indications do not include weight loss. If the user’s kidney function is not good, it may cause kidney damage after use, and the sugar content in the urine is too high, the urinary tract is prone to infection, and even more serious, Ketoacidosis with fatal risk.

Also because it is not a legal weight-loss drug, once there is a physical problem, drug injury relief cannot be applied.

☆Health news will never be missed, click like to follow the fan page.


☆For more important medical news, please go to Liberty Health.com.

keywords

  • diabetes

  • lose weight

  • hypoglycemic drugs

  • thin pen

related news